TY - JOUR
T1 - Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis
AU - Aylon, Yael
AU - Furth, Noa
AU - Mallel, Giuseppe
AU - Friedlander, Gilgi
AU - Nataraj, Nishanth Belugali
AU - Dong, Meng
AU - Hassin, Ori
AU - Zoabi, Rawan
AU - Cohen, Benjamin
AU - Drendel, Vanessa
AU - Salame, Tomer Meir
AU - Mukherjee, Saptaparna
AU - Harpaz, Nofar
AU - Johnson, Randy
AU - Aulitzky, Walter E.
AU - Yarden, Yosef
AU - Shema, Efrat
AU - Oren, Moshe
N1 - Funding Information:
We thank James Martin (Baylor College of Medicine, Houston, TX, USA) for the generous sharing of conditional knockout mice. We thank Dr. Ron Rotkopf (Bioinformatics Life Science Core Facility, Weizmann Institute, Israel) for bioinformatic help and Ziv Porath (Flow Cytometry Unit, Department of Biological Services, Weizmann Institute, Israel) for assistance with ImageStream analyses. Dr. Werner Schroth (University of Tuebingen, Stuttgart, Germany) who provided us with the breast cancer FFPE blocks and patient data from his study collection, and Ms. Kerstin Willecke (University of Tuebingen, Stuttgart, Germany) for performing IHC staining on the human patient samples. This work was supported in part by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (Grant G-201906-00324 to M.O.), the Robert Bosch Stiftung GmbH, and the Berthold Leibinger Stiftung GmbH (Grant 123493 to M.O.), the Rising Tide Foundation (Grant 136467 to M.O.), the United States–Israel Binational Science Foundation (BSF), Jerusalem, Israel (Grant 2019045 to M.O.), Anat and Amnon Shashua (Grant 721972 to M.O.), and the Moross Integrated Cancer Center. M.O. is the incumbent of the Andre Lwoff chair in molecular biology. G.F. is incumbent of the David and Stacey Cynamon Research fellow Chair in Genetics and Personalized Medicine.
Funding Information:
We thank James Martin (Baylor College of Medicine, Houston, TX, USA) for the generous sharing of conditional knockout mice. We thank Dr. Ron Rotkopf (Bioinformatics Life Science Core Facility, Weizmann Institute, Israel) for bioinformatic help and Ziv Porath (Flow Cytometry Unit, Department of Biological Services, Weizmann Institute, Israel) for assistance with ImageStream analyses. Dr. Werner Schroth (University of Tuebingen, Stuttgart, Germany) who provided us with the breast cancer FFPE blocks and patient data from his study collection, and Ms. Kerstin Willecke (University of Tuebingen, Stuttgart, Germany) for performing IHC staining on the human patient samples. This work was supported in part by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (Grant G-201906-00324 to M.O.), the Robert Bosch Stiftung GmbH, and the Berthold Leibinger Stiftung GmbH (Grant 123493 to M.O.), the Rising Tide Foundation (Grant 136467 to M.O.), the United States–Israel Binational Science Foundation (BSF), Jerusalem, Israel (Grant 2019045 to M.O.), Anat and Amnon Shashua (Grant 721972 to M.O.), and the Moross Integrated Cancer Center. M.O. is the incumbent of the Andre Lwoff chair in molecular biology. G.F. is incumbent of the David and Stacey Cynamon Research fellow Chair in Genetics and Personalized Medicine.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Breast cancer, the most frequent cancer in women, is generally classified into several distinct histological and molecular subtypes. However, single-cell technologies have revealed remarkable cellular and functional heterogeneity across subtypes and even within individual breast tumors. Much of this heterogeneity is attributable to dynamic alterations in the epigenetic landscape of the cancer cells, which promote phenotypic plasticity. Such plasticity, including transition from luminal to basal-like cell identity, can promote disease aggressiveness. We now report that the tumor suppressor LATS1, whose expression is often downregulated in human breast cancer, helps maintain luminal breast cancer cell identity by reducing the chromatin accessibility of genes that are characteristic of a “basal-like” state, preventing their spurious activation. This is achieved via interaction of LATS1 with the NCOR1 nuclear corepressor and recruitment of HDAC1, driving histone H3K27 deacetylation near NCOR1-repressed “basal-like” genes. Consequently, decreased expression of LATS1 elevates the expression of such genes and facilitates slippage towards a more basal-like phenotypic identity. We propose that by enforcing rigorous silencing of repressed genes, the LATS1-NCOR1 axis maintains luminal cell identity and restricts breast cancer progression.
AB - Breast cancer, the most frequent cancer in women, is generally classified into several distinct histological and molecular subtypes. However, single-cell technologies have revealed remarkable cellular and functional heterogeneity across subtypes and even within individual breast tumors. Much of this heterogeneity is attributable to dynamic alterations in the epigenetic landscape of the cancer cells, which promote phenotypic plasticity. Such plasticity, including transition from luminal to basal-like cell identity, can promote disease aggressiveness. We now report that the tumor suppressor LATS1, whose expression is often downregulated in human breast cancer, helps maintain luminal breast cancer cell identity by reducing the chromatin accessibility of genes that are characteristic of a “basal-like” state, preventing their spurious activation. This is achieved via interaction of LATS1 with the NCOR1 nuclear corepressor and recruitment of HDAC1, driving histone H3K27 deacetylation near NCOR1-repressed “basal-like” genes. Consequently, decreased expression of LATS1 elevates the expression of such genes and facilitates slippage towards a more basal-like phenotypic identity. We propose that by enforcing rigorous silencing of repressed genes, the LATS1-NCOR1 axis maintains luminal cell identity and restricts breast cancer progression.
UR - http://www.scopus.com/inward/record.url?scp=85142908550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142908550&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-34863-9
DO - 10.1038/s41467-022-34863-9
M3 - Article
C2 - 36443319
AN - SCOPUS:85142908550
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 7199
ER -